Drug Database
IM

imatinib mesilate

✓ Approved

Dako · KIT · Companion diagnostic

What is imatinib mesilate?

imatinib mesilate is a companion diagnostic developed by Dako. It is approved for therapeutic indications via others.

Drug Profile

CompanyDako
Drug ClassCompanion diagnostic
Molecular TargetKIT
RouteOthers
StatusApproved
Sources: ClinicalTrials.gov, Dako

Mechanism of Action

Molecular Targets

imatinib mesilate acts on 1 molecular target:

KITKIT proto-oncogene, receptor tyrosine kinase (MASTC, CD117)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

imatinib mesilate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancer✓ Approved

Related Research Articles

PubMedJournal of gastrointestinal cancer2026-07-17

Neoadjuvant Imatinib Therapy in Rectal Gastrointestinal Stromal Tumors: A Comprehensive Narrative Review of Tumor Downsizing, Sphincter Preservation, Transanal Surgical Platforms, Functional Outcomes, and Survival.

Raja Naga Praneeth NP, Kandagari Nagapavani N

Rectal gastrointestinal stromal tumors (GISTs) represent approximately 5-8.5% of all GISTs and pose unique surgical challenges due to the confined pelvic anatomy and proximity to the anal sphincter complex. Historically, radical surgery - including abdominoperineal resection (APR) or pelvic exenteration - was frequently required for complete tumor clearance, resulting in permanent colostomy and significant functional morbidity. The introduction of imatinib mesylate, a selective tyrosine kinase inhibitor (TKI) targeting KIT and PDGFRA, has fundamentally transformed the management of rectal GIST. Neoadjuvant imatinib therapy achieves significant tumor downsizing (25-46% reduction), reduces mitotic activity, and enables sphincter-preserving surgery in patients who would otherwise require radical resection. The concurrent evolution of transanal endoscopic platforms - including transanal endoscopic microsurgery (TEM), transanal minimally invasive surgery (TAMIS), and robotic TAMIS (R-TAMIS) - has further expanded the possibilities for organ preservation, achieving R0 resection rates of 89-100% with favorable functional outcomes and preserved fecal continence. Emerging evidence also suggests improvements in distant recurrence-free survival, disease-specific survival, and overall survival compared with upfront surgery. This comprehensive narrative review examines the rationale, efficacy, response assessment, surgical implications, the role of transanal surgical platforms, functional outcomes, quality of life, survival outcomes, and current guideline recommendations for neoadjuvant imatinib in rectal GIST.

PMID 42467291
Read full article →
PubMedJournal of clinical and translational science2026-07-17

Individual patient data meta-analysis and systematic review evaluating camostat mesilate to treat COVID-19.

Hedlin Haley H, Tobback Els E, Lee Justin J, Wang Yiwen Y et al.

In the COVID-19 pandemic, several phase II and III randomized trials were launched to evaluate the effectiveness of camostat, an orally administered TMPRSS2 inhibitor previously approved for other indications, for treating SARS-CoV-2 infections. Owing to the rapidly changing landscape during the pandemic, many of these trials were unable to reach completion. Further, methods for synthesizing trials that were launched and not completed were critical. This systematic review aimed to consolidate global evidence by identifying placebo controlled, randomized trials of camostat and analyzing their collective clinical and virologic impact on SARS-CoV-2 through an individual patient data meta-analysis (IPDMA). We harmonized data from the studies and utilized Bayesian statistical models to assess virologic outcomes (measured by the rate of change in viral shedding) and clinical outcomes (based on the time to the first of two consecutive symptom-free days), adjusting for age and sex. The IPDMA incorporated data from six countries, totaling 431 patients across the studies; 118 patients contributed data for the primary virologic outcome and 240 for the clinical symptom outcome. Camostat did not improve the rate of change in viral load (difference in rate of change = 0.11 Ct value/day higher, 95% credible interval 2.04 lower to 2.23 higher) or time to symptom resolution (hazard ratio = 0.87, 95% credible interval 0.51, 1.55) when compared to placebo. Despite its theoretically promising mode of action, camostat did not demonstrate a statistically significant virologic or clinical benefit in treating COVID-19, highlighting the complexity of drug repurposing in emergency health situations.

PMID 42465050
Read full article →
PubMedScientific reports2026-07-17

Characteristics of Staphylococcus lugdunensis isolated from humans and animals.

Prorok Paulina P, Skrok Milena M, Karwańska Magdalena M, Siedlecka Magdalena M et al.

Staphylococcus lugdunensis is an opportunistic coagulase-negative Staphylococcus increasingly reported in both humans and companion animals. In this study, we performed a comprehensive characterization of S. lugdunensis isolates obtained from different hosts and clinical backgrounds. Species identification was conducted using MALDI-TOF MS and confirmed by PCR targeting the species-specific fbl gene, complemented by partial rpoB sequencing. The isolates were analysed using multilocus sequence typing (MLST), PCR-based detection of antimicrobial resistance genes, and phenotypic antimicrobial susceptibility testing. Biofilm formation was assessed using a crystal violet microtiter plate assay under different incubation temperatures, and the virulence of selected strains was evaluated using the Galleria mellonella larvae infection model. The isolates exhibited genetic diversity and variable antimicrobial resistance and biofilm phenotypes. Among the analysed isolates, biofilm production was significantly influenced by incubation temperature and host origin, and selected strains caused differential larval survival in the G. mellonella model. Collectively, these findings highlight the heterogeneity of the analysed S. lugdunensis collection comprising human- and animal-derived isolates and support the need for further studies within the One Health framework.

PMID 42463811
Read full article →
PubMedJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy2026-07-17

Mycoplasma Pneumonia Diagnostic Prediction Score: Is it possible to differentiate between Mycoplasma pneumoniae pneumonia and SARS-CoV-2 pneumonia?

Miyashita Naoyuki N, Nakamori Yasushi Y, Ogata Makoto M, Fukuda Naoki N et al.

The Mycoplasma Pneumonia Diagnostic Prediction Score, recommended in pneumonia guidelines, is a useful method for differentiating Mycoplasma pneumoniae pneumonia from bacterial pneumonia. On the other hand, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a common microorganism in community-acquired pneumonia, so we investigated whether the Mycoplasma Score can differentiate between M. pneumoniae pneumonia and SARS-CoV-2 pneumonia. Analysis was performed on 162 patients with M. pneumoniae, 422 patients with the Ancestral strain, 262 with the Alpha variant, 274 with the Delta variant, and 1,241 with the Omicron variant. When using the Mycoplasma Score, the sensitivity for predicting M. pneumoniae pneumonia was 71.8%. The diagnostic specificity was 81.3% for the Ancestral strain, 81.7% for the Alpha variant, 77.4% for the Delta variant, and 88.2% for the Omicron variant. The specificity for all SARS-CoV-2 pneumonia cases was 84.8%. When targeting the currently circulating Omicron variant, the diagnostic specificity ranged from 83.9% to 92.7%, showing differences among subvariants. Differences between the two groups were identified using four parameters: age, underlying disease, severity of cough, and use of rapid diagnostic methods. When comparing M. pneumoniae pneumonia and SARS-CoV-2 pneumonia, the diagnostic sensitivity of the Mycoplasma Pneumonia Diagnostic Prediction Score was 71.8%, and the diagnostic specificity was 84.8%. However, when targeting the currently circulating SARS-CoV-2 Omicron variant pneumonia, the diagnostic specificity increased to 88.2%, suggesting that it is possible to differentiate between M. pneumoniae pneumonia and SARS-CoV-2 pneumonia. However, the specificity is lower than that for differentiating bacterial pneumonia.

PMID 42463011
Read full article →
PubMedCureus2026-07-17

Aggressive B-cell Lymphoma Masquerading as Benign Epstein-Barr Virus (EBV)-Related Splenomegaly: An Analysis of Diagnostic Anchoring Bias.

Savadkar Amrut A, Chauhan Ipsita I, Sharma Mansi M, Rallabandi Suhasini S et al.

We report a case involving a 52-year-old male who was initially diagnosed with Epstein-Barr virus (EBV)-related splenomegaly and subsequently identified as having an aggressive B-cell lymphoproliferative disorder. Despite multiple initial diagnostic tests yielding negative results, persistent clinical suspicion due to the worsening patient's condition warranted further investigation, ultimately establishing the correct diagnosis. This case underscores the diagnostic challenges in distinguishing benign viral-associated splenomegaly from underlying malignant lymphoproliferative disorders and highlights the importance of maintaining clinical vigilance when initial diagnostic findings are discordant with the clinical presentation.

PMID 42465140
Read full article →
PubMedBMC medical education2026-07-17

Enhancing ultrasound training for breast cancer diagnosis: a controlled study of AI-assisted learning.

Wu Shuang S, Wang Weihao W, Wu Jian J, Zhou Hong H et al.

This study aimed to develop and evaluate an AI-assisted teaching platform to enhance diagnostic competency in breast ultrasound. The goal was to assess whether AI integration improves diagnostic accuracy, learning efficiency, and participant satisfaction within a residency training program. We conducted a cohort-based study at our hospital. Twelve junior residents (experimental group) underwent AI-assisted training via a newly implemented platform, while twelve senior residents (control group) completed conventional training. Diagnostic performance was evaluated before and after the one-month intervention using consistent assessments. Participant satisfaction was surveyed across domains including learning engagement, skill development, and confidence. In the experimental group, post-intervention diagnostic scores (90.50 ± 9.82) were significantly higher than pre-intervention diagnostic scores(70.00 ± 17.55, P = 0.003,95%CI[-32.54,-8.46], Cohen's d=-1.44). Survey results indicated high satisfaction: 83.33% strongly agreed the platform facilitated learning, 66.67% reported improved pattern recognition, and 66.67% noted increased engagement in self-learning. A majority also reported gains in clinical reasoning and confidence when facing a real patient. We integrated an AI-assisted platform into ultrasound residency training, creating an educational tool. In this single-center exploratory study, the AI-assisted platform shows potential to improve residents' diagnostic skills for breast ultrasound.

PMID 42464241
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about imatinib mesilate